Bio-Rad price target raised to $450 from $400 at Citi

Citi raised the firm’s price target on Bio-Rad (BIO) to $450 from $400 and keeps a Buy rating on the shares. The company reported solid Q3 results, the analyst tells investors in a research note. The firm says the “clean quarter is certainly welcomed by investors after a challenging stretch of execution.”